Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.

@article{Butera2018MutantPP,
  title={Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.},
  author={Giovanna Butera and R. Pacchiana and Nidula Mullappilly and Marilena Margiotta and S. Bruno and P. Conti and C. Riganti and M. Donadelli},
  journal={Biochimica et biophysica acta. Molecular cell research},
  year={2018},
  volume={1865 12},
  pages={
          1914-1923
        }
}
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and devastating human malignancies. In about 70% of PDACs the tumor suppressor gene TP53 is mutated generally resulting in conformational changes of mutant p53 (mutp53) proteins, which acquire oncogenic functions triggering aggressiveness of cancers and alteration of energetic metabolism. Here, we demonstrate that mutant p53 prevents the nuclear translocation of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase… Expand
Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
TLDR
The results showed that DHSA treatment inhibited cell proliferation, migration and invasion in a time- and dose-dependent manner and led to induction of cell cycle arrest and apoptosis, offering the novel perspective thatDHSA inhibits pancreatic cancer cells through a bidirectional regulation between mut-p53/-Ras and WT-p 53/-RAS to restore the dynamic balance by Ras and p53 proteins. Expand
Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells.
TLDR
MnSOD induction as a defense mechanism of melanoma cells to counterbalance the pro-oxidant conditions induced by mutant p53 is suggested, and SIRT3 and MnSOD act to maintain ROS levels controlled to promote cell proliferation and survival. Expand
Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells
TLDR
The studies summarized here highlight that GOF mutant p53 isoforms might constitute major targets for selective therapeutic intervention against several types of tumors and that ROS enhancement driven by Mutant p53 might represent an “Achilles heel” of cancer cells, suggesting pro-oxidant drugs as a therapeutic approach for cancer patients bearing the mutant TP53 gene. Expand
Nuclear GAPDH is vital for hypoxia-induced hepatic stellate cell apoptosis and is indicative of aggressive hepatocellular carcinoma behavior
TLDR
Findings provide a novel mechanism underlying the involvement of intranuclear GAPDH in hypoxia-induced HSCs apoptosis and a correlation between nuclear GAPDh levels and the clinical prognosis, which may prompt the development of a novel therapeutic strategy for HCC. Expand
The complexity of p53-mediated metabolic regulation in tumor suppression.
TLDR
The roles of p53 in the regulation of glucose, lipid, amino acid, nucleotide, iron metabolism, and ROS production are summarized and the mechanisms underlying p53-mediated ferroptosis, AKT/mTOR signaling as well as autophagy are highlighted. Expand
The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells
TLDR
The functional effect of the hot-spot p53 mutant isoforms R175H and R273H on cancer cell secretome is reported, showing their influence on proliferation, chemoresistance, apoptosis, and autophagy, as well as cell migration and epithelial-mesenchymal transition. Expand
PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer
TLDR
A novel mutant p53/KLF5‐PLA2G16 regulatory axis on tumour growth and glycolysis in PAAD is revealed and was associated with unfavourable survival. Expand
The enhancement of glycolysis regulates pancreatic cancer metastasis
TLDR
In an extremely nutrient-deficient and hypoxic environment resulting from uncontrolled growth, vascular disturbances and desmoplastic reactions, pancreatic cancer cells utilize “metabolic reprogramming” to satisfy their energy demand and support malignant behaviors such as metastasis. Expand
Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders
TLDR
The molecular mechanisms and the cellular effects of GAPDH aggregates, which are correlated with mitochondrial malfunctions and can be considered a potential therapeutic target for various diseases, including cancer and neurodegenerative disorders are summarized. Expand
Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis
TLDR
It is suggested that targeting mutant p53, via its reactivation to the wild-type form, may serve as a promising therapeutic strategy for many cancers that harbor mutant p51, and not only will this strategy abrogate Mutant p53 GOF, but it will also restore WT p53 tumor-suppressive functions. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 62 REFERENCES
Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
TLDR
A novel mechanism through which mutant p53 proteins promote cancer cell proliferation with the concomitant inhibition of autophagy is revealed. Expand
Mutant p53 and mTOR/PKM2 regulation in cancer cells
TLDR
It is hypothesize that mTOR/PKM2 pathway stimulation serves to sustain the oncogenic activity of mutant p53 through both the enhancement of chemoresistance and of aerobic glycolysis of cancer cells. Expand
Molecular interplay between mutant p53 proteins and autophagy in cancer cells.
TLDR
This review analytically summarizes recent findings, which indicate that gain-of-function (GOF) mutant p53 proteins counteract the autophagic machinery by various molecular mechanisms including the regulation of AMPK and Akt/mTOR pathways, autophagy-related genes (ATGs), HIF-1α target genes, and the mitochondrial citrate carrier CIC. Expand
p53 and glucose metabolism: an orchestra to be directed in cancer therapy.
TLDR
This review emphasizes the p53 activation as a promising therapeutic strategy to reprogram tumor glucose metabolism, conducting to cell death, and potential synergisms between p53-activating agents and metabolic inhibitors are discussed, fostering the improvement of cancer therapy. Expand
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
TLDR
The results show that gemcitabine aberrantly stimulates mutant p53 activity in PDAC cells identifying key processes with potential for therapeutic targeting and support an anti-tumoral strategy based on inhibition of autophagy combined with p53 activation and standard chemotherapy. Expand
UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism
TLDR
It is demonstrated that inhibition of UCP2 triggers Akt/mTOR pathway in a ROS‐dependent mechanism in pancreatic adenocarcinoma cells, creating the conditions for the synergistic counteraction of cancer cell growth with the mTOR inhibitor everolimus. Expand
Tumor-Associated Mutant p53 Drives the Warburg Effect
TLDR
It is shown that tumor-associatedmutp53 stimulates the Warburg effect in cultured cells and mutp53 knock-in mice as a new mutp 53 gain-of-function (GOF) and a mechanism for controlling the Warberg effect is revealed. Expand
Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions
TLDR
In resected PDAC samples, higher proliferation and expression of glycolysis genes correlated with poor patient survival, and the stimulatory effect of SIRT1 on proliferation and glyCOlysis gene expression was confirmed in a human PDAC cell line. Expand
Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear Translocation*
TLDR
The study suggests that activated Akt2 may increase ovarian cancer cell survival via inhibition of GAPDH-induced apoptosis, which is partly mediated by its phosphorylation ofGAPDH at Thr-237, which results in the inhibition of gAPDH nuclear translocation. Expand
Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis.
TLDR
Novel findings concerning the regulation of secreted molecules by cancer cells bearing mutant TP53 gene are summarized, suggesting that mutant p53 proteins are able to alter the secretion of enzymes involved in the modulation of extracellular matrix components and regulate the crosstalk between cancer and stromal cells. Expand
...
1
2
3
4
5
...